This Article Abstract Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ferrara, N. Search for Related Content PubMed PubMed Citation Articles by Ferrara, N.

Vascular Endothelial Growth Factor as a Target for Anticancer Therapy

Genentech, Inc., South San Francisco, California, USA

Correspondence: Napoleone Ferrara, M.D., Genentech, Inc., One DNA Way, South San Francisco, California 94080, USA. Telephone: 650-225-2968; Fax: 650-225-6443; e-mail: nf{at}gene.com

	LEARNING OBJECTIVES

Top Learning Objectives Abstract Introduction Angiogenesis and Its Role... VEGF in Normal and... Significance of VEGF in... Targeting VEGF: Implications for... Conclusions References

 
After completing this course, the reader will be able to:

1. Explain the biology of angiogenesis.
   
2. Identify the role of VEGF in normal and tumor angiogenesis.
   
3. Describe the key ways in which VEGF has been targeted in cancer therapy.
   

	ABSTRACT

Top Learning Objectives Abstract Introduction Angiogenesis and Its Role... VEGF in Normal and... Significance of VEGF in... Targeting VEGF: Implications for... Conclusions References

 
The development of a vascular supply is a critical factor in the growth and metastatic spread of malignant tumors. Of the multitude of growth factors that regulate physiological and pathological angiogenesis, vascular endothelial growth factor (VEGF) is believed to be the most important. There is evidence that overexpression of VEGF is correlated with an adverse prognosis, at least in some tumors. Tumor-expressed VEGF is particularly attractive as a target for anticancer therapy because its angiogenesis-promoting activity is at the level of the endothelial cell and, compared with agents that directly target tumor cells, tumor penetration is less critical for VEGF inhibitors. Moreover, recent work has shown that inhibiting tumor angiogenesis increases the effectiveness of coadministered chemotherapy and radiotherapy. This suggests that drugs that target VEGF or its receptors can be combined with traditional treatment modalities to ensure maximum effectiveness. A variety of agents aimed at blocking VEGF or its receptor-signaling system are currently being developed for the treatment of cancer. Of these, bevacizumab, a humanized monoclonal antibody directed at VEGF, is the most advanced in clinical development and has shown promising results in clinical trials.

Key Words. Vascular endothelial growth factor • Angiogenesis • Cancer • Monoclonal antibody • Bevacizumab

	INTRODUCTION

Top Learning Objectives Abstract Introduction Angiogenesis and Its Role... VEGF in Normal and... Significance of VEGF in... Targeting VEGF: Implications for... Conclusions References

 
Chemotherapy has been the cornerstone of cancer treatment for several decades. However, chemotherapeutic agents have considerable nonspecific toxicities that limit the dosages that can be given. Moreover, development of resistance to treatment is common. Recent years have seen the advent of a new generation of agents that directly target either the malignant cell itself or cells supporting tumor growth.

Strategies targeting tumor angiogenesis have been a focus of intense research over the past decade, following observations that the growth and metastatic spread of tumors are dependent on their development of a vascular supply [1, 2]. This research effort has led to the isolation of an array of factors that mediate both positive and negative regulation of angiogenesis, with the most pivotal positive regulator being vascular endothelial growth factor (VEGF) [3, 4]. This review examines the central role that VEGF plays in angiogenesis, both in the normal physiological setting as well as in the context of cancer, with a particular focus on the application of current concepts to the development of new anticancer therapies.

	ANGIOGENESIS AND ITS ROLE IN TUMOR GROWTH

Top Learning Objectives Abstract Introduction Angiogenesis and Its Role... VEGF in Normal and... Significance of VEGF in... Targeting VEGF: Implications for... Conclusions References

 
The vascular system is composed of two major cell types: vascular endothelial cells, lining the interior of blood vessels as a monolayer, and smooth muscle cells, which regulate intravascular pressure.

During embryogenesis, the formation of the cardiovascular system proceeds through an initial stage termed vasculogenesis, in which the endothelial cells differentiate from mesodermal precursors, followed by angiogenesis, the elaboration of the tubular network of endothelial cells. This process requires a series of steps, including endothelial cell activation, basement membrane degradation, cell migration, extracellular matrix invasion, endothelial cell proliferation, and capillary lumen formation. Subsequent stabilization of the vascular network involves the reversal of these processes, with the reestablishment of the basement membrane, cessation of cell proliferation, junctional complex formation, and recruitment of pericytes to support the vessel wall.

Angiogenesis continues throughout development, with new capillaries forming by sprouting or splitting from preformed vessels, followed by remodeling, as the organism grows to final form. In the adult, physiological angiogenesis continues, albeit at a much reduced level, and is associated primarily with maintenance of the vasculature, and with wound healing and menstrual cycling [3, 5–8].

Angiogenesis is essential for the growth of most primary tumors and their subsequent metastasis (Fig. 1). Tumors can absorb sufficient nutrients and oxygen by simple diffusion up to a size of 1–2 mm, at which point their further growth requires the elaboration of a vascular supply. This process is thought to involve recruitment of the neighboring host mature vasculature to begin sprouting new blood vessel capillaries, which grow toward, and subsequently infiltrate, the tumor mass [9]. In addition, both physiological and tumor angiogenesis involve the recruitment of circulating endothelial precursor cells from the bone marrow to promote neovascularization [10, 11].

View larger version (92K): [in this window] [in a new window]   Figure 1. Angiogenesis is a necessary condition for sustained tumor growth.

Both physiologic and tumor angiogenesis are regulated by a host of growth factors in the microenvironment (Table 1), some of which, such as VEGF, are highly specific for endothelial cells, while others, such as basic fibroblast growth factor (bFGF) and the matrix metalloproteinases (MMPs), have a much broader range of action. Activating factors can be produced by the tumors themselves, by the surrounding tissue, or by infiltrating macrophages and fibroblasts [8]. The majority of the activating compounds exert their actions through endothelial cell surface receptors, for which they serve as ligands, ultimately leading to secretion of additional angiogenic factors. In addition, hypoxia, hypoglycemia, and mechanical stress can serve as stimuli [8]. In the case of the matrix metalloproteinases, the stimulation is thought to reflect the proteolysis of basement membrane constituents, such as heparan sulfate proteoglycans, and the consequent release of sequestered growth factors [13].

View larger version (36K): [in this window] [in a new window]   Figure 2. Molecular events in cancer.

	VEGF IN NORMAL AND TUMOR ANGIOGENESIS

Top Learning Objectives Abstract Introduction Angiogenesis and Its Role... VEGF in Normal and... Significance of VEGF in... Targeting VEGF: Implications for... Conclusions References

 
Families of VEGF-Related Compounds and Their Receptors
VEGF, which is also termed VEGF-A or vascular permeability factor, belongs to the VEGF-platelet-derived growth factor (PDGF) supergene family; other family members include VEGF-B, VEGF-C, VEGF-D, and VEGF-E (a virally encoded protein), all showing varying degrees of homology with VEGF. Alternative splicing of the VEGF gene yields four isoforms of 121, 165, 189, and 206 amino acids, and other less frequent splice variants. VEGF-165, a 45-kiloDalton (kD) homodimeric glycoprotein, is the dominant form and is, in part, secreted and, in part, matrix bound. Both VEGF-189 and VEGF-206 are basic, with a high affinity for heparin, and remain sequestered in the extracellular matrix, presumably to heparan sulfate proteoglycans. VEGF-121 is acidic, does not bind heparin, and is secreted. The matrix-sequestered forms may be released by enzymatic action, either through the action of heparinase or through cleavage by plasmin to release a diffusible fragment (VEGF-110). The actions of VEGF-165 involve the activation of proteinase cascades, including that leading to plasmin generation, so the consequent plasmin-mediated release of matrix-bound VEGF isoforms provides an amplification mechanism [21].

VEGF actions are mediated through binding to two receptor tyrosine kinases, VEGFR-1 (Flt-1) and VEGFR-2 (KDR; whose murine form is known as Flk-1). Activation of these receptors by VEGF triggers the phosphorylation of a multitude of proteins that are active in signal transduction cascades [3]. Other members of the VEGF family show different receptor-binding specificities, with VEGF-B and placental growth factor (PIGF) binding and activating only VEGFR-1. VEGF-C and VEGF-D bind a third receptor, VEGFR-3 (Flt-4), through which they mediate lymphangiogenesis [22, 23], and also show some activity toward VEGFR-2. Both VEGFR-1 and VEGFR-2 are found predominantly on the surfaces of vascular endothelial cells, where they bind VEGF with high affinity. Although VEGFR-1 binds with higher affinity, it is believed to act primarily as a decoy receptor, modulating the availability of VEGF to VEGFR-2, the principal receptor for VEGF signaling [3, 24]. Further modulatory actions are exerted by a soluble form of VEGFR-1, which binds VEGF and can inhibit VEGF-induced mitogenesis, as well as the neuropilins, receptors for the collapsin/semaphorin family. Neuropilin-2 binds to VEGFR-1, while neuropilin-1 binds to VEGF-165 and increases its affinity for VEGFR-2 by approximately one order of magnitude [25].

VEGF gene expression is upregulated by a host of stimuli, including estrogen, nitric oxide (NO), and a variety of growth factors, such as fibroblast growth factor-4, PDGF, tumor necrosis factor alpha (TNF-), epidermal growth factor (EGF), transforming growth factor beta (TGF-ß), keratinocyte growth factor, interleukin (IL)-6, IL-1ß, and insulin-like growth factor 1 (IGF-1) (Fig. 3) [3, 25, 26]. Consistent with its role in tumor angiogenesis, expression of VEGF is upregulated by the common genetic events leading to malignant transformation, including loss of tumor suppressor genes, such as p53, and activation of oncogenes, such as ras, v-src, and HER2 [15]. Moreover, VEGF expression is particularly sensitive to oxygen tension and is rapidly upregulated by the hypoxia that characterizes most tumors, which is due to the aberrant nature of their vascular supply [27]. Shweiki et al. noted that, in glioblastoma multiforme tumors, the maximal expression of VEGF mRNA was found in necrotic (and presumably hypoxic) regions [28].

View larger version (16K): [in this window] [in a new window]   Figure 3. VEGF: a central role in tumor vasculature development and maintenance. Abbreviations: DC = dendritic cells; tPA = tissue-type plasminogen activator; uPA = urokinase-type plasminogen activator; uPAr = urokinase receptor; eNOS = endothelic nitric oxide synthase; COX-2 = cyclooxygenase-2.

Actions of VEGF in Angiogenesis
VEGF is a growth factor that is essential for the regulation of both physiological and pathological angiogenesis. It also plays a pivotal role in embryonic vasculogenesis, to the extent that deleting only one allele results in death of the embryo [29]. As described above, angiogenesis is a multistep process, and VEGF acts at several stages (Fig. 4):

View larger version (45K): [in this window] [in a new window]   Figure 4. Multiple functions of VEGF. Abbreviations: EC = endothelial cell; EPC = endothelial progenitor cell. Reprinted from Toi et al. [24] with permission from Elsevier.

• VEGF is a potent mitogen for vascular endothelial cells, but, with a few exceptions, is not mitogenic for other cell types [21].
  
• VEGF mediates the secretion and activation of enzymes involved in degrading the extracellular matrix. Acting on endothelial cells, VEGF induces expression of plasminogen activator and its inhibitor [30], expression of the urokinase receptor [31], and expression of the matrix metalloproteinases interstitial collagenase and gelatinase A, while decreasing levels of tissue inhibitors of metalloproteinases 1 and 2 [32, 33].
  
• VEGF acts as a survival factor for endothelial cells through the inhibition of apoptosis [34]. This action is mediated through the induction of expression of the antiapoptotic proteins Bcl-2 and Bcl-A1, regulation of the phosphatidylinositol 3-kinase/Akt pathway, increased phosphorylation of focal adhesion kinase, and stimulation of endothelial cell production of NO and prostaglandin I2 [35, 36].
  
• VEGF is essential for the mobilization of bonemarrow-derived endothelial cell precursors in the promotion of vascularization [10].
  
• In addition to promoting division of endothelial cells, VEGF also has an important role in modulating their migration to sites of angiogenesis [37].
  

Other actions of VEGF include increasing vascular permeability [38], inhibition of dendritic cell differentiation [39], upregulation of hexose transport into endothelial cells [40], induction of tissue factor [41], and induction of monocyte migration [42].

Owing to the amount of VEGF that tumors produce, a positive feedback loop is created, wherein VEGF-induced promotion of angiogenesis allows for enhanced tumor growth, which in turn results in increased VEGF secretion. This type of amplification can be further enhanced through the VEGF-mediated upregulation of expression of the VEGF receptors in endothelial cells [43]. In addition, tumor angiogenesis recruits bone-marrow-derived endothelial precursor cells, a process that is also dependent on VEGF and that can be completely ablated if signaling through both VEGFR-1 and VEGFR-2 is inhibited [11].

	SIGNIFICANCE OF VEGF IN CANCER

Top Learning Objectives Abstract Introduction Angiogenesis and Its Role... VEGF in Normal and... Significance of VEGF in... Targeting VEGF: Implications for... Conclusions References

 
VEGF expression is increased in the majority of cancers examined to date. The list is extensive and includes hematological malignancies [44]; colon and rectal cancers [45]; liver cancer [46]; lung, thyroid, breast, gastrointestinal tract, kidney, and bladder cancers; ovary and uterine cervix carcinomas; angiosarcomas; germ-cell tumors; and intracranial tumors [21]. The correlation is not absolute, however, and varies depending on the particular study. For instance, in patients with colorectal cancer, Lee et al. found that approximately half of their patients showed elevated VEGF expression levels [45], whereas Tokunaga et al. reported that all of the 61 patients they observed had tumors that expressed VEGF [46]. In several studies involving breast cancer, colorectal cancer, and ovarian cancer, elevated VEGF levels were monitored after tumor resection and declined dramatically, with levels tending to rise again if the cancers recurred [47].

Several factors combine to contribute to more serious disease in instances of elevated VEGF expression. First, the role of VEGF in promoting the development of tumor vasculature supports this essential component of tumor development. Moreover, many tumors express VEGF receptors, so that VEGF can act as a paracrine factor, leading to a feedback loop not only through the stimulation of vascularization, but also through direct action on the tumor cells themselves. In this context, it can both promote the growth of transformed cell lines in vitro [48] and act as a survival factor for cancer cells through enhanced expression of the antiapoptotic factors Bcl-2 [49] and survivin [50]. VEGF-mediated inhibition of dendritic cell differentiation [39] may underlie the deficit of dendritic-cell infiltration that has been observed in gastric carcinoma tissues, suggesting that VEGF causes reduced immune surveillance of tumors [51]. Perhaps most importantly, the report that VEGF is essential for vascularization at very early stages of tumor formation by transformed cells implies that this growth factor is a key promoter of metastasis [51].

Thus, it is not surprising that VEGF expression in the primary tumor has been correlated in many studies with a greater risk for recurrence and poor prognosis in a variety of human cancers, including acute myeloid leukemia, breast cancer, colon cancer, hepatocellular carcinoma, non-small cell lung cancer, and ovarian cancer [8]. High VEGF levels have been found in malignant effusions, and it is thought that the permeability-enhancing effects of VEGF may promote effusion [24]. Elevated VEGF levels may also contribute to increased resistance to chemotherapy or endocrine therapy in advanced breast cancer [52]. Accordingly, VEGF status has proved to be of value in predicting the effectiveness of radiotherapy, chemotherapy, and hormonal therapy, as well as the likelihood of relapse, in a variety of cancers [24, 47].

	TARGETING VEGF: IMPLICATIONS FOR THERAPY

Top Learning Objectives Abstract Introduction Angiogenesis and Its Role... VEGF in Normal and... Significance of VEGF in... Targeting VEGF: Implications for... Conclusions References

 
The application of angiogenesis inhibitors as anticancer agents is in its early stages, but over 25 drugs are under study in clinical trials. These inhibitors fall into several functional categories, including inhibitors of growth factors, endothelial cell signal transduction, endothelial cell proliferation, matrix metalloproteinases, endothelial cell survival, and bone marrow precursor cells [53]. Experience from these trials has brought new principles and challenges, many of which are likely to be applicable to drugs targeting VEGF.

Given its central role in promoting many cancers, VEGF provides an attractive target for therapeutic intervention. Two considerations in particular deserve emphasis: VEGF has a strategic position in the regulation of tumor angiogenesis, as it serves as a point of integration of a variety of upstream and downstream signals (Fig. 3), leading ultimately to stimulation of the endothelial cell; and VEGF promotes angiogenesis by acting directly on the endothelial cell, a genetically stable entity, rather than on genetically labile tumor cells. Accordingly, it has been suggested that, in contrast to drugs that inhibit angiogenesis indirectly through the inhibition of tumor-derived angiogenic factors, drugs that act to inhibit VEGF signaling may be less susceptible to selection of mutations that confer resistance [18]. However, recent evidence suggests that tumors can become resistant to antiangiogenic drugs, possibly through genetic mutations and instabilities associated with tumor cells [54, 55].

It is difficult for conventional therapies to gain adequate access to tumor tissue, first, because of the aberrant vasculature—highly tortuous with many blind ends—that characterizes most tumors [56], and second, because drug penetration into tumor tissue is diminished because interstitial pressure is elevated in most tumors, owing to severe leakage from the vasculature [57]. This latter effect is probably attributable to the actions of VEGF in enhancing vascular permeability. These factors are compounded by the secondary effects of radiotherapy and chemotherapy, which lead to local regions of hypoxia and induction of VEGF expression. The overproduction of VEGF not only exacerbates the high tumor interstitial pressure, but also protects tumor cells against the apoptosis that is normally induced by conventional therapies [49]. In principle, angiogenesis inhibitors, by targeting the vasculature rather than the tumor cells, should be able to circumvent the problem posed by high interstitial pressures in the tumors, since they do not require access to the tumor tissue.

Perhaps the most dramatic observation from recent studies has been the finding that coadministration of angiogenesis inhibitors with chemotherapy and radiotherapy can enhance the efficacy of these standard treatments. While it might be expected that drugs that target the tumor blood supply would exacerbate these difficulties, making the tumor cells even less accessible as the vasculature retracts, the reverse has been found in practice. Teicher et al. found that coadministration of the angiogenesis inhibitor TNR-470, a fumagillin analog, both enhanced both the permeability of murine tumors and led to a dramatic increase in cyclophosphamide-induced tumor cell killing [58]. Jain argued that this reflects a normalization of the tumor vasculature by angiogenesis inhibitors, so that some of the aberrant tumor blood vessels are pruned away as a result of endothelial cell death [56].

Moreover, many chemotherapy and radiotherapy regimens induce VEGF expression, which may contribute to tumor resistance to apoptosis-inducing modalities. Inhibition of VEGF or its receptors potentiates radiation-mediated killing of cancer cells, presumably by inhibiting the radiation-induced increase in VEGF and subsequent hypoxia [59, 60]. Indeed, an anti-VEGF antibody augmented the tumor response under normoxic and hypoxic conditions [59].

A variety of therapeutic strategies aimed at blocking VEGF or its receptor signaling system are currently being developed for the treatment of neoplastic diseases. VEGF/VEGFR blockade by monoclonal antibodies and inhibition of receptor signaling by tyrosine kinase inhibitors are the best studied approaches. VEGFR-1 ribozymes, VEGF toxin conjugates, and soluble VEGF receptors are also being investigated. Of these, bevacizumab (rhuMAb VEGF; Avastin^TM; Genentech, Inc.; South San Francisco, CA), a humanized monoclonal antibody directed at VEGF, is the most advanced in clinical development and has shown promising results in clinical trials.

	CONCLUSIONS

Top Learning Objectives Abstract Introduction Angiogenesis and Its Role... VEGF in Normal and... Significance of VEGF in... Targeting VEGF: Implications for... Conclusions References

 
The ongoing development of angiogenesis inhibitors as cancer therapies is a further example of the principle that a fundamental understanding of physiological processes can lead to new therapies. VEGF has been shown to have central roles in key signaling pathways that mediate angiogenesis and in tumor growth and metastasis. Accordingly, therapies directed against VEGF or its receptors hold great promise in cancer treatment.

Key advantages of targeting VEGF include: by targeting the endothelial cell, rather than the tumor itself, issues of accessibility to the tumor interior are avoided and drug resistance may be less likely; given the central role of VEGF in both tumor growth and the establishment of metastases, its inhibition should prove effective at all stages of cancer, with the prevention of metastasis being a particular benefit; coadministration of therapies against VEGF with chemotherapy or radiotherapy is likely to lead to greater efficacies of these traditional therapies by preventing VEGF-mediated potentiation of cell survival, and given that targeting angiogenesis avoids the nonspecific toxicities associated with chemotherapy, there is ample scope for empirical combination, both with other antiangiogenesis therapies and with traditional chemotherapy and radiotherapy, to provide maximal flexibility in tailoring treatment options for the individual patient.

Most recently, this modality has received validation in a large, phase III clinical trial in metastatic colorectal cancer patients. Bevacizumab plus chemotherapy resulted in a highly significant longer time to progression and greater survival than chemotherapy alone [61].

	REFERENCES

Top Learning Objectives Abstract Introduction Angiogenesis and Its Role... VEGF in Normal and... Significance of VEGF in... Targeting VEGF: Implications for... Conclusions References

 

1. Algire GH, Chalkley HW, Legallais FY et al. Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 1945;6:73–85.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182–1186.
3. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669–676.[CrossRef][Medline]
4. Ferrara N. VEGF and the quest for tumour angiogenesis factors. Nat Rev Cancer 2002;2:795–803.[CrossRef][Medline]
5. Risau W, Flamme I. Vasculogenesis. Annu Rev Cell Dev Biol 1995;11:73–91.[CrossRef][Medline]
6. Risau W. Mechanisms of angiogenesis. Nature 1997;386:671–674.[CrossRef][Medline]
7. Miller KD, Sweeney CJ, Sledge GW Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001;19:1195–1206.[Abstract/Free Full Text]
8. Rosen LS. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control 2002;9(suppl):36–44.[Medline]
9. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000;21:505–515.[Abstract/Free Full Text]
10. Asahara T, Takahashi T, Masuda H et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999;18:3964–3972.[CrossRef][Medline]
11. Lyden D, Hattori K, Dias S et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat Med 2001;7:1194–1201.[CrossRef][Medline]
12. Holash J, Maisonpierre PC, Compton D et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999;284:1994–1998.[Abstract/Free Full Text]
13. Pupa SM, Menard S, Forti S et al. New insights into the role of extracellular matrix during tumor onset and progression. J Cell Physiol 2002;192:259–267.[CrossRef][Medline]
14. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353–364.[CrossRef][Medline]
15. Rak J, Yu JL, Klement G et al. Oncogenes and angiogenesis: signaling three-dimensional tumor growth. J Investig Dermatol Symp Proc 2000;5:24–33.[CrossRef][Medline]
16. Li CY, Shan S, Huang Q et al. Initial stages of tumor cell-induced angiogenesis: evaluation via skin window chambers in rodent models. J Natl Cancer Inst 2000;92:143–147.[Abstract/Free Full Text]
17. Weidner N, Semple JP, Welch WR et al. Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma. N Engl J Med 1991;324:1–8.[Abstract]
18. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727–739.[CrossRef][Medline]
19. Hasan J, Byers R, Jayson GC. Intra-tumoural microvessel density in human solid tumours. Br J Cancer 2002;86:1566–1577.[CrossRef][Medline]
20. Sledge GW Jr, Miller KD. Angiogenesis and antiangiogenic therapy. Curr Probl Cancer 2002;26:1–60.[Medline]
21. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4–25.[Abstract/Free Full Text]
22. Jussila L, Alitalo K. Vascular growth factors and lymphangiogenesis. Physiol Rev 2002;82:673–700.[Abstract/Free Full Text]
23. Karkkainen MJ, Makinen T, Alitalo K. Lymphatic endothelium: a new frontier of metastasis research. Nat Cell Biol 2002;4:E2–E5.[CrossRef][Medline]
24. Toi M, Matsumoto T, Bando H. Vascular endothelial growth factor: its prognostic, predictive, and therapeutic implications. Lancet Oncol 2001;2:667–673.[CrossRef][Medline]
25. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 2001;26:25–35.[CrossRef][Medline]
26. Neufeld G, Cohen T, Gengrinovitch S et al. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 1999;13:9–22.[Abstract/Free Full Text]
27. Shweiki D, Itin A, Soffer D et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843–845.[CrossRef][Medline]
28. Shweiki D, Itin A, Neufeld G et al. Patterns of expression of vascular endothelial growth factor (VEGF) and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis. J Clin Invest 1993;91:2235–2243.
29. Ferrara N, Carver-Moore K, Chen H et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 1996;380:439–442.[CrossRef][Medline]
30. Pepper MS, Ferrara N, Orci L et al. Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor-1 in microvascular endothelial cells. Biochem Biophys Res Commun 1991;181:902–906.[CrossRef][Medline]
31. Mandriota SJ, Seghezzi G, Vassalli JD et al. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 1995;270:9709–9716.[Abstract/Free Full Text]
32. Unemori EN, Ferrara N, Bauer EA et al. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cell Physiol 1992;153:557–562.[CrossRef][Medline]
33. Lamoreaux WJ, Fitzgerald ME, Reiner A et al. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 1998;55:29–42.[CrossRef][Medline]
34. Alon T, Hemo I, Itin A et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995;1:1024–1028.[CrossRef][Medline]
35. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am J Physiol Cell Physiol 2001;280:C1358–C1366.[Abstract/Free Full Text]
36. Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 2001;280:C1375–C1386.[Abstract/Free Full Text]
37. Rousseau S, Houle F, Huot J. Integrating the VEGF signals leading to actin-based motility in vascular endothelial cells. Trends Cardiovasc Med 2000;10:321–327.[CrossRef][Medline]
38. Senger DR, Galli SJ, Dvorak AM et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983;219:983–985.[Abstract/Free Full Text]
39. Gabrilovich D, Ishida T, Oyama T et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998;92:4150–4166.[Abstract/Free Full Text]
40. Pekala P, Marlow M, Heuvelman D et al. Regulation of hexose transport in aortic endothelial cells by vascular permeability factor and tumor necrosis factor-alpha, but not by insulin. J Biol Chem 1990;265:18051–18054.[Abstract/Free Full Text]
41. Mechtcheriakova D, Schabbauer G, Lucerna M et al. Specificity, diversity and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells. FASEB J 2001;15:230–242.[Abstract/Free Full Text]
42. Barleon B, Sozzani S, Zhou D et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996;87:3336–3343.[Abstract/Free Full Text]
43. Shen BQ, Lee DY, Gerber HP et al. Homologous up-regulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro. J Biol Chem 1998;273:29979–29985.[Abstract/Free Full Text]
44. List AF. Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies. The Oncologist 2001;6(suppl 5):24–31.[Abstract/Free Full Text]
45. Lee JC, Chow NH, Wang ST et al. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 2000;36:748–753.
46. Tokunaga T, Oshika Y, Abe Y et al. Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer. Br J Cancer 1998;77:998–1002.[Medline]
47. Poon RT, Fan ST, Wong J. Clinical implications of circulating angiogenic factors in cancer patients. J Clin Oncol 2001;19:1207–1225.[Abstract/Free Full Text]
48. Masood R, Cai J, Zheng T et al. Vascular endothelial growth factor (VEGF) is an autocrine growth factor for VEGF receptor-positive human tumors. Blood 2001;98:1904–1913.[Abstract/Free Full Text]
49. Harmey JH, Bouchier-Hayes D. Vascular endothelial growth factor (VEGF), a survival factor for tumour cells: implications for anti-angiogenic therapy. Bioessays 2002;24:280–283.[CrossRef][Medline]
50. Tran J, Master Z, Yu JL et al. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002;99:4349–4354.[Abstract/Free Full Text]
51. Saito H, Tsujitani S, Ikeguchi M et al. Relationship between the expression of vascular endothelial growth factor and the density of dendritic cells in gastric adenocarcinoma tissue. Br J Cancer 1998;78:1573–1577.[Medline]
52. Pegram MD, Reese DM. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor. Semin Oncol 2002;29(suppl 11):29–37.
53. Kerbel RS. Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. J Clin Oncol 2001;19(suppl):45S–51S.
54. Marx J. Cancer research. Obstacle for promising cancer therapy. Science 2002;295:1444.
55. Yu JL, Rak JW, Coomber BL et al. Effect of p53 status on tumor response to antiangiogenic therapy. Science 2002;295:1526–1528.[Abstract/Free Full Text]
56. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987–989.[CrossRef][Medline]
57. Jain RK. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J Natl Cancer Inst 1989;81:570–576.[Free Full Text]
58. Teicher BA, Holden SA, Ara G et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 1994;57:920–925.[Medline]
59. Lee CG, Heijn M, di Tomaso E et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60:5565–5570.[Abstract/Free Full Text]
60. Gorski DH, Mauceri HJ, Salloum RM et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 1998;58:5686–5689.[Abstract/Free Full Text]
61. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin for the treatment of metastatic colorectal cancer: results of a randomized phase III trial. N Engl J Med 2004 (in press).

This article has been cited by other articles:

				M. Damianovich, M. Blank, A. Raiter, B. Hardy, and Y. Shoenfeld Anti-vascular endothelial growth factor (VEGF) specific activity of intravenous immunoglobulin (IVIg) Int. Immunol., September 1, 2009; 21(9): 1057 - 1063. [Abstract] [Full Text] [PDF]

				C. C. Milsom, J. L. Yu, N. Mackman, J. Micallef, G. M. Anderson, A. Guha, and J. W. Rak Tissue Factor Regulation by Epidermal Growth Factor Receptor and Epithelial-to-Mesenchymal Transitions: Effect on Tumor Initiation and Angiogenesis Cancer Res., December 15, 2008; 68(24): 10068 - 10076. [Abstract] [Full Text] [PDF]

				M. Aleku, P. Schulz, O. Keil, A. Santel, U. Schaeper, B. Dieckhoff, O. Janke, J. Endruschat, B. Durieux, N. Roder, et al. Atu027, a Liposomal Small Interfering RNA Formulation Targeting Protein Kinase N3, Inhibits Cancer Progression Cancer Res., December 1, 2008; 68(23): 9788 - 9798. [Abstract] [Full Text] [PDF]

				E. L. Bradshaw-Pierce, C. A. Steinhauer, D. Raben, and D. L. Gustafson Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma Mol. Cancer Ther., September 1, 2008; 7(9): 3006 - 3017. [Abstract] [Full Text] [PDF]

				C. A. Heckman, T. Holopainen, M. Wirzenius, S. Keskitalo, M. Jeltsch, S. Yla-Herttuala, S. R. Wedge, J. M. Jurgensmeier, and K. Alitalo The Tyrosine Kinase Inhibitor Cediranib Blocks Ligand-Induced Vascular Endothelial Growth Factor Receptor-3 Activity and Lymphangiogenesis Cancer Res., June 15, 2008; 68(12): 4754 - 4762. [Abstract] [Full Text] [PDF]

				S. E. Strome, E. A. Sausville, and D. Mann A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects Oncologist, September 1, 2007; 12(9): 1084 - 1095. [Abstract] [Full Text] [PDF]

				Z. Zhou, M. F. Bolontrade, K. Reddy, X. Duan, H. Guan, L. Yu, D. J. Hicklin, and E. S. Kleinerman Suppression of Ewing's Sarcoma Tumor Growth, Tumor Vessel Formation, and Vasculogenesis Following Anti Vascular Endothelial Growth Factor Receptor-2 Therapy Clin. Cancer Res., August 15, 2007; 13(16): 4867 - 4873. [Abstract] [Full Text] [PDF]

				G. J. Riely and V. A. Miller Vascular Endothelial Growth Factor Trap in Non Small Cell Lung Cancer Clin. Cancer Res., August 1, 2007; 13(15): 4623s - 4627s. [Abstract] [Full Text] [PDF]

				F. Pisati, M. Belicchi, F. Acerbi, C. Marchesi, C. Giussani, M. Gavina, S. Javerzat, M. Hagedorn, G. Carrabba, V. Lucini, et al. Effect of Human Skin-Derived Stem Cells on Vessel Architecture, Tumor Growth, and Tumor Invasion in Brain Tumor Animal Models Cancer Res., April 1, 2007; 67(7): 3054 - 3063. [Abstract] [Full Text] [PDF]

				G. Giaccone The Potential of Antiangiogenic Therapy in Non-Small Cell Lung Cancer Clin. Cancer Res., April 1, 2007; 13(7): 1961 - 1970. [Abstract] [Full Text] [PDF]

				S. Senan and E. F. Smit Design of Clinical Trials of Radiation Combined with Antiangiogenic Therapy Oncologist, April 1, 2007; 12(4): 465 - 477. [Abstract] [Full Text] [PDF]

				L. Bozulic, P. J. Morin, T. Hunter, and B. A. Hemmings Meeting Report: Targeting the Kinome--20 Years of Tyrosine Kinase Inhibitor Research in Basel Sci. Signal., February 20, 2007; 2007(374): pe8 - pe8. [Abstract] [Full Text] [PDF]

				B. I. Rini Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions Clin. Cancer Res., February 15, 2007; 13(4): 1098 - 1106. [Abstract] [Full Text] [PDF]

				X. Chen, J. Lin, T. Kanekura, J. Su, W. Lin, H. Xie, Y. Wu, J. Li, M. Chen, and J. Chang A Small Interfering CD147-Targeting RNA Inhibited the Proliferation, Invasiveness, and Metastatic Activity of Malignant Melanoma Cancer Res., December 1, 2006; 66(23): 11323 - 11330. [Abstract] [Full Text] [PDF]

				B. Kim, S. Suvas, P. P. Sarangi, S. Lee, R. A. Reisfeld, and B. T. Rouse Vascular Endothelial Growth Factor Receptor 2-Based DNA Immunization Delays Development of Herpetic Stromal Keratitis by Antiangiogenic Effects J. Immunol., September 15, 2006; 177(6): 4122 - 4131. [Abstract] [Full Text] [PDF]

				S M Hyder Sex-steroid regulation of vascular endothelial growth factor in breast cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 667 - 687. [Abstract] [Full Text] [PDF]

				M Milano and O Guerin Recent advances in targeted therapies for colorectal cancer Journal of Oncology Pharmacy Practice, June 1, 2006; 12(2): 69 - 73. [Abstract] [PDF]

				M. Jeltsch, T. Karpanen, T. Strandin, K. Aho, H. Lankinen, and K. Alitalo Vascular Endothelial Growth Factor (VEGF)/VEGF-C Mosaic Molecules Reveal Specificity Determinants and Feature Novel Receptor Binding Patterns J. Biol. Chem., April 28, 2006; 281(17): 12187 - 12195. [Abstract] [Full Text] [PDF]

				M. Tzukerman, T. Rosenberg, I. Reiter, S. Ben-Eliezer, G. Denkberg, R. Coleman, Y. Reiter, and K. Skorecki The influence of a human embryonic stem cell-derived microenvironment on targeting of human solid tumor xenografts. Cancer Res., April 1, 2006; 66(7): 3792 - 3801. [Abstract] [Full Text] [PDF]

				A. K. Malik, M. E. Baldwin, F. Peale, G. Fuh, W.-C. Liang, H. Lowman, G. Meng, N. Ferrara, and H.-P. Gerber Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice Blood, January 15, 2006; 107(2): 550 - 557. [Abstract] [Full Text] [PDF]

				S. Van Schaeybroeck, A. Karaiskou-McCaul, D. Kelly, D. Longley, L. Galligan, E. Van Cutsem, and P. Johnston Epidermal Growth Factor Receptor Activity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combination with Chemotherapy Clin. Cancer Res., October 15, 2005; 11(20): 7480 - 7489. [Abstract] [Full Text] [PDF]

				Y. Yamazaki, Y. Matsunaga, Y. Nakano, and T. Morita Identification of Vascular Endothelial Growth Factor Receptor-binding Protein in the Venom of Eastern Cottonmouth: A NEW ROLE OF SNAKE VENOM MYOTOXIC LYS49-PHOSPHOLIPASE A2 J. Biol. Chem., August 26, 2005; 280(34): 29989 - 29992. [Abstract] [Full Text] [PDF]

				S. H. Lee, D. Lopes de Menezes, J. Vora, A. Harris, H. Ye, L. Nordahl, E. Garrett, E. Samara, S. L. Aukerman, A. B. Gelb, et al. In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer Models Clin. Cancer Res., May 15, 2005; 11(10): 3633 - 3641. [Abstract] [Full Text] [PDF]

				L. Manenti, E. Riccardi, S. Marchini, E. Naumova, I. Floriani, A. Garofalo, R. Dossi, E. Marrazzo, D. Ribatti, E. Scanziani, et al. Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy Mol. Cancer Ther., May 1, 2005; 4(5): 715 - 725. [Abstract] [Full Text] [PDF]

				S. M. Short, A. Derrien, R. P. Narsimhan, J. Lawler, D. E. Ingber, and B. R. Zetter Inhibition of endothelial cell migration by thrombospondin-1 type-1 repeats is mediated by {beta}1 integrins J. Cell Biol., February 14, 2005; 168(4): 643 - 653. [Abstract] [Full Text] [PDF]

				H.-P. Gerber and N. Ferrara Pharmacology and Pharmacodynamics of Bevacizumab as Monotherapy or in Combination with Cytotoxic Therapy in Preclinical Studies Cancer Res., February 1, 2005; 65(3): 671 - 680. [Abstract] [Full Text] [PDF]

				N. H. Fernando and H. I. Hurwitz Targeted Therapy of Colorectal Cancer: Clinical Experience with Bevacizumab Oncologist, June 1, 2004; 9(suppl_1): 11 - 18. [Abstract] [Full Text] [PDF]

				R. S. Herbst and A. B. Sandler Non-Small Cell Lung Cancer and Antiangiogenic Therapy: What Can Be Expected of Bevacizumab? Oncologist, June 1, 2004; 9(suppl_1): 19 - 26. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ferrara, N. Search for Related Content PubMed PubMed Citation Articles by Ferrara, N.